A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to
evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90
years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis
related to AD.
The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo
in the treatment of subjects with psychosis associated with AD as measured by the
Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.